Phenotypic correction of lipid storage and growth arrest in Wolman disease fibroblasts by gene transfer of lysosomal acid lipase

U. J.F. Tietge, G. Sun, S. Czarnecki, Q. C. Yu, P. Lohse, Hong Du, G. A. Grabowski, J. M. Glick, D. J. Rader

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Wolman disease is a lethal lysosomal storage disease due to deficiency of lysosomal acid lipase (LAL). Wolman disease is characterized by pronounced hepatic involvement while neurological symptoms are uncommon, making Wolman disease an attractive candidate for liver-directed gene therapy. This study was performed to test the effects of gene replacement in fibroblasts lacking LAL, using a recombinant adenovirus encoding the human LAL cDNA (AdhLAL). Human fibroblasts from a Wolman disease patient were infected with AdhLAL and showed a dose-dependent increase in LAL protein and activity up to 5-fold above levels in control fibroblasts. Furthermore, 72 hr after infection with AdhLAL there was a dose-dependent correction of the severe lipid storage phenotype of Wolman disease fibroblasts. Electron microscopy confirmed significant correction of the lysosomal lipid storage in AdhLAL-infected Wolman disease fibroblasts at the ultrastructural level. Intravenous injection of AdhLAL into wild-type mice resulted in a 13.5-fold increase in hepatic LAL activity, and overexpression of LAL was not associated with toxic side effects. These data demonstrate high-level lysosomal expression of recombinant LAL in vitro and in vivo and show the feasibility of gene therapeutic strategies for the treatment of Wolman disease.

Original languageEnglish (US)
Pages (from-to)279-289
Number of pages11
JournalHuman Gene Therapy
Volume12
Issue number3
DOIs
StatePublished - Feb 10 2001
Externally publishedYes

Fingerprint

Wolman Disease
Sterol Esterase
Fibroblasts
Human Adenoviruses
Lipids
Complementary DNA
Growth
Genes
Liver
Lysosomal Storage Diseases
Adenoviridae Infections
Poisons
Adenoviridae
Intravenous Injections
Genetic Therapy
Electron Microscopy
Phenotype

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Phenotypic correction of lipid storage and growth arrest in Wolman disease fibroblasts by gene transfer of lysosomal acid lipase. / Tietge, U. J.F.; Sun, G.; Czarnecki, S.; Yu, Q. C.; Lohse, P.; Du, Hong; Grabowski, G. A.; Glick, J. M.; Rader, D. J.

In: Human Gene Therapy, Vol. 12, No. 3, 10.02.2001, p. 279-289.

Research output: Contribution to journalArticle

Tietge, UJF, Sun, G, Czarnecki, S, Yu, QC, Lohse, P, Du, H, Grabowski, GA, Glick, JM & Rader, DJ 2001, 'Phenotypic correction of lipid storage and growth arrest in Wolman disease fibroblasts by gene transfer of lysosomal acid lipase', Human Gene Therapy, vol. 12, no. 3, pp. 279-289. https://doi.org/10.1089/10430340150218413
Tietge, U. J.F. ; Sun, G. ; Czarnecki, S. ; Yu, Q. C. ; Lohse, P. ; Du, Hong ; Grabowski, G. A. ; Glick, J. M. ; Rader, D. J. / Phenotypic correction of lipid storage and growth arrest in Wolman disease fibroblasts by gene transfer of lysosomal acid lipase. In: Human Gene Therapy. 2001 ; Vol. 12, No. 3. pp. 279-289.
@article{34c5507f1d414623be7026652cd1e97b,
title = "Phenotypic correction of lipid storage and growth arrest in Wolman disease fibroblasts by gene transfer of lysosomal acid lipase",
abstract = "Wolman disease is a lethal lysosomal storage disease due to deficiency of lysosomal acid lipase (LAL). Wolman disease is characterized by pronounced hepatic involvement while neurological symptoms are uncommon, making Wolman disease an attractive candidate for liver-directed gene therapy. This study was performed to test the effects of gene replacement in fibroblasts lacking LAL, using a recombinant adenovirus encoding the human LAL cDNA (AdhLAL). Human fibroblasts from a Wolman disease patient were infected with AdhLAL and showed a dose-dependent increase in LAL protein and activity up to 5-fold above levels in control fibroblasts. Furthermore, 72 hr after infection with AdhLAL there was a dose-dependent correction of the severe lipid storage phenotype of Wolman disease fibroblasts. Electron microscopy confirmed significant correction of the lysosomal lipid storage in AdhLAL-infected Wolman disease fibroblasts at the ultrastructural level. Intravenous injection of AdhLAL into wild-type mice resulted in a 13.5-fold increase in hepatic LAL activity, and overexpression of LAL was not associated with toxic side effects. These data demonstrate high-level lysosomal expression of recombinant LAL in vitro and in vivo and show the feasibility of gene therapeutic strategies for the treatment of Wolman disease.",
author = "Tietge, {U. J.F.} and G. Sun and S. Czarnecki and Yu, {Q. C.} and P. Lohse and Hong Du and Grabowski, {G. A.} and Glick, {J. M.} and Rader, {D. J.}",
year = "2001",
month = "2",
day = "10",
doi = "10.1089/10430340150218413",
language = "English (US)",
volume = "12",
pages = "279--289",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Phenotypic correction of lipid storage and growth arrest in Wolman disease fibroblasts by gene transfer of lysosomal acid lipase

AU - Tietge, U. J.F.

AU - Sun, G.

AU - Czarnecki, S.

AU - Yu, Q. C.

AU - Lohse, P.

AU - Du, Hong

AU - Grabowski, G. A.

AU - Glick, J. M.

AU - Rader, D. J.

PY - 2001/2/10

Y1 - 2001/2/10

N2 - Wolman disease is a lethal lysosomal storage disease due to deficiency of lysosomal acid lipase (LAL). Wolman disease is characterized by pronounced hepatic involvement while neurological symptoms are uncommon, making Wolman disease an attractive candidate for liver-directed gene therapy. This study was performed to test the effects of gene replacement in fibroblasts lacking LAL, using a recombinant adenovirus encoding the human LAL cDNA (AdhLAL). Human fibroblasts from a Wolman disease patient were infected with AdhLAL and showed a dose-dependent increase in LAL protein and activity up to 5-fold above levels in control fibroblasts. Furthermore, 72 hr after infection with AdhLAL there was a dose-dependent correction of the severe lipid storage phenotype of Wolman disease fibroblasts. Electron microscopy confirmed significant correction of the lysosomal lipid storage in AdhLAL-infected Wolman disease fibroblasts at the ultrastructural level. Intravenous injection of AdhLAL into wild-type mice resulted in a 13.5-fold increase in hepatic LAL activity, and overexpression of LAL was not associated with toxic side effects. These data demonstrate high-level lysosomal expression of recombinant LAL in vitro and in vivo and show the feasibility of gene therapeutic strategies for the treatment of Wolman disease.

AB - Wolman disease is a lethal lysosomal storage disease due to deficiency of lysosomal acid lipase (LAL). Wolman disease is characterized by pronounced hepatic involvement while neurological symptoms are uncommon, making Wolman disease an attractive candidate for liver-directed gene therapy. This study was performed to test the effects of gene replacement in fibroblasts lacking LAL, using a recombinant adenovirus encoding the human LAL cDNA (AdhLAL). Human fibroblasts from a Wolman disease patient were infected with AdhLAL and showed a dose-dependent increase in LAL protein and activity up to 5-fold above levels in control fibroblasts. Furthermore, 72 hr after infection with AdhLAL there was a dose-dependent correction of the severe lipid storage phenotype of Wolman disease fibroblasts. Electron microscopy confirmed significant correction of the lysosomal lipid storage in AdhLAL-infected Wolman disease fibroblasts at the ultrastructural level. Intravenous injection of AdhLAL into wild-type mice resulted in a 13.5-fold increase in hepatic LAL activity, and overexpression of LAL was not associated with toxic side effects. These data demonstrate high-level lysosomal expression of recombinant LAL in vitro and in vivo and show the feasibility of gene therapeutic strategies for the treatment of Wolman disease.

UR - http://www.scopus.com/inward/record.url?scp=0035835371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035835371&partnerID=8YFLogxK

U2 - 10.1089/10430340150218413

DO - 10.1089/10430340150218413

M3 - Article

C2 - 11177564

AN - SCOPUS:0035835371

VL - 12

SP - 279

EP - 289

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -